Valo Therapeutics Seals €19 Million Capital Raise
Deal News | Mar 10, 2025 | CDP Venture Capital
Valo Therapeutics, a biotechnology company focused on immunotherapy for cancer treatment, has successfully closed a €19 million capital raise. The infusion of capital will enable Valo Therapeutics to advance its experimental oncological treatments, aiming to enhance its innovative immunological therapy. The financial backing underscores the confidence of investors, including CDP Venture Capital, in the potential of Valo Therapeutics to make significant strides in cancer treatment through its novel therapeutic approaches.
Sectors
- Biotechnology
- Healthcare
Geography
- Italy – Italy is relevant because CDP Venture Capital, a key investor in Valo Therapeutics, is based there.
Industry
- Biotechnology – Biotechnology is relevant as it involves the development of Valo Therapeutics’ innovative cancer immunotherapy.
- Healthcare – Healthcare is relevant because the advancements and applications of Valo Therapeutics’ treatments are focused within the healthcare sector, particularly in oncology.
Financials
- €19 million – The amount raised by Valo Therapeutics in its capital increase to fund experimental cancer therapies.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Valo Therapeutics | Target Company | Company | A biotechnology company involved in developing innovative immunotherapy treatments for cancer. |
| CDP Venture Capital | Investor | Company | A private equity firm providing financial backing to Valo Therapeutics to support its oncology developments. |